

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Applicant:

Hadi ASLAN et al

Serial No.:

10/520,271

Filed:

January 14, 2005

For:

METHODS OF IMPLANTING MESENCHYMAL

STEM CELLS FOR TISSUE REPAIR AND

FORMATION

Examiner: WEHBE, ANNE MARIE SABRINA

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

€ Alexandria, VA 22313-1450

8888888

Group Art Unit: 1633

Attorney

Docket: 28921

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> Respectfully submitted, Martin O Mopulan

Martin D. Moynihan

Registration No. 40,338

Dated: December 15, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known				
					Application Number 10/520,271				
	INFORMATION DISCLOSURE						Filing Date	Janua	ary 14, 2005
	STA	TEMENT BY APP	LICAN	VT	First Named Inventor	Hadi ASLAN et al			
	(use as many sheets as nec	essary)		Art Unit				
					Examiner Name	WEF	IBE, ANNE MARIE		
						SAB	RINA		
Sheet		1	of	3	Attorney Docket Number	2892	1		
			U.S.	PATENT	DOCUMENTS				
Examiner Initials*	No. 1		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ^{2 (if known)}	05 14 0	202					
	1	US-6,387,367	05-14-20		Davis-Sproul et al.				
	2	US-5,965,436	10-12-19		Thiede et al.				
	3	US-6,043,066	03-28-20		Mangano et al.				
	4	US-5,486,359	01-23-19	996	Caplan et al.				
			_						
1000							16		
	 -								
			L						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ : Number ⁴ : Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	5	PCT WO 93/00050	07-7-1993	Ron et al.					
							├		
							H		
	<u> </u>								
Examiner Signature					Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

a me Paperv	vork Reduction	Act of 1995, no persons are required to	respond to a col	lection of information ur	it and Trademark Office: U.S. iless it contains a valid OMB contr	ol number.				
		stitute for form 1449A/PTO		_	Complete Application Number	II IZIIOWI				
	INFORMATION DISCLOSURE						520,271			
	INF	Filing Date		y 14, 2005						
	STATEMENT BY APPLICANT				First Named Inventor Group Art Unit		SLAN et al			
	<u> </u>					1633	BE, ANNE			
(use as many sheets as necessary)					Examiner Name		E SABRINA			
Sheet	2	Of		3	Attorney Docket Number	28921	B 5/ IBICITY			
-	 -		RT – NON		ATURE DOCUMENTS					
Examiner	Cite	Include name of the author (in	CAPITAL LE	TTERS), title of the a	article (when appropriate), title	of the				
Initials	No.1	item (book, magazine, journal	, serial sympos	sium, catalog, etc.) da	te, page(s), volume-issue numl		T^2			
		publisher, city and/or country where published. Clarke et al. "Mesenchymal Cell Precursors From Human Bone Marrow Have A								
	6									
		Phenotype That Is Distinct From Cultured Mesenchymal Cells and Are Exclusively Present in A Small Subset of CD451° SH2+ Cells", Blood, 98(11 Part 1): 85a, 2001.								
		Abstract # 355.	01 CD431	SH2+ Cells", Bio	οοα, 98(11 Paπ 1): 85a, .	2001.				
	7	Quirici et al. "Isolation of	Pone Morre	ou Masanahumal	Stom Calla by Anti Nor					
	'	Growth Factor Receptor A								
		2000.	viitioodies ,	Experimental He	matology, 30(7). 763-75	′1,				
	8	Devine et al. "Mesenchyn	nal Stem Ce	lls Are Canable o	f Homing to the Bone M	arrow				
	0	of Non-Human Primates 1								
		29(2): 244-255, 2001.	onowing b	ystemie imasion	, Experimental Hematol	ogy,				
	9	Caplan et al. "Mesenchym	al StemCel	ls: Building Block	k for Molecular Medicin	e in	-			
		the 21st Cebtury", Trens i				`				
	10	Gronthos et al. "The Grov				arrow				
		Stromal Precursors Serum								
		1995.			, =, (.). , , = ,	,				
	11	Fridenshtein "Stromal Bo	ne Marrow	Cells and the Hen	natopoietic					
		Microenvironment", Arkh								
	12	Haynesworth et al. "Chara				luman	·			
		Marrow", Bone, 13: 81-88			G					
	13	Horowitz et al. "Transplan		Therapeutic Effe	ects of Bone Marrow-De	rived				
		Mesenchymal Cells in Ch								
	-	5(3): 309-313, 1999.			•	,				
	14	Kadiyala et al. "Culture E	xpanded Ca	nine Mesenchym	al Stem Cells Possess					
		Osteochondrogenic Poten	tial In Vivo	and In Vitro", Ce	ell Transplantation, 6(2):	125-				
		134, 1997.								
	15	Krebsbach et al. "Repair of			Bone Marrow Stromal (Cells",				
		Transplantation, 66(10): 1								
	16	Keunmyoung et al. "Hum								
· · · · · · ·		Expression during Expans								
	17	Liechty et al. "Human me								
		differentiation after in ute	ro transplan	tation in sheep",	Nature Medicine, 6(11):	1282-				
		1286, 2000.								
	18	Mackay et al. "Chondroge				Stem				
		Cells from Marrow", Tiss								
	19	Majumdar et al. "Isolation								
		Bone Marrow-Derived M	ultipotential	i Stromal Cells, Jo	ournal of Cellular Physic	ology,				
	120	185: 98-106, 2000.	E1 C	• .• •), D : 1					
	20	Majumdar et al. "Cutting								
	•	Mesenchymal Stem Cells								
		Long-Term Hematopoies				;				
	21	Lineages", Journal of Her				la"				
	21	Pittenger etal. "Multilinea		i or Adult Human	iviesenchymai Stem Ce.	is",				
	22	Science, 284: 143-147, 19		tom Colle Differen	ntiata ta a Cardiamera and		<u> </u>			
	22	Toma et al. "Human Meso				۳				
	22	Phenotype in the Adult M				m for				
	23	Turgeman et al. "Enginee Skeletal Cell Mediated Go								
	1	I preferat cell integrated Q	опе тпетару	, incodulial of	Gene ivicultile, 3: 240-	∠J1,				

24	Yoo et al. "The Cohondrogenic Potential of Human Bone-Marrow-Derived Mesenchymal Progenitor Cells", Journal of Bone and Joint Surgery, 80-A(12): 1745-1757, 1998.	
25	Young et al. "Use of Mesenchymal Stem Cells in a Collagen Matrix for Achilles Tendon Repair", Journal of the Orthopaedic Research, 16: 406-413, 1998.	
26	Pittenger et al. "Human Mesenchymal Stem Cells Can Be Directed Into chondrocytes, Adipocytes and Osteocytes" Mol. Biol. Cell. 1996 &:305a Abstract only.	

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{**}EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation is no conformance and not considered. Include copy of this form with next communication to applicant.

**Applicant's unique citation designation number (optional). **Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.